Goldline Pharmaceutical IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 |
| Expense | 19.45 | 21.04 | 24.20 |
| Profit (PAT) | 0.26 | 1.81 | 2.83 |
| Total Assets | 19.39 | 22.93 | 26.28 |
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 12.57 | 10 |
| Chandra Bhagat Pharma Limited | 1.14 | 37.73 | 3 |
Promoters: Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
Strengths & Risks
- Heavily oversubscribed — 840.6x overall (so far).
- Strong institutional (QIB) demand — 180.2x.
- Revenue grew 19% in the latest reported year.
- Solid profit margin — 10.1%.
- Strong return on equity — 36%.
- Elevated leverage — debt/equity of 1.50.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy. The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Goldline Pharmaceutical Ltd., 103, F-1, Leela Apartment, Shilpa HSG Society,, Near Saptagiri Nagar, Shanidham,, Narendra Nagar,, Nagpur, Maharashtra, 440015
| Purpose | Amount (Cr) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| General Corporate Purpose | - |
Resources & Documents
Goldline Pharmaceutical has set a price band of Rs 41–Rs 43 per share for an issue size of Rs 12 crore. The stock listed with a 38.95% gain versus its issue price on May 19, 2026.
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1.
The issue is promoted by Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal with Cumulative Capital Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (Rs 9 crore) and General Corporate Purpose.
On fundamentals, the company is posting revenue growth of 19.1%, a profit margin of 10.1%, return on equity of 35.8% in its most recent reported period. Listed peers in this segment include Mono Pharmacare Limited (P/E 12.57x, market cap Rs 10 crore) and Chandra Bhagat Pharma Limited (P/E 37.73x, market cap Rs 3 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Goldline Pharmaceutical IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Goldline Pharmaceutical GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!